PolyTherics (United Kingdom) a preclinical-stage biochemistry company focused on pegylation technologies, closed a $3.5M Series C financing. Participants include Beringea, Imperial Innovation and The Capital Fund.
Thanx for your patience as we catch-up.

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital
Thanx for your patience as we catch-up.

Breathe America (Nashville, TN) a commercial-stage clinical company focused on the treatment of chronic airway diseases, allergy, sinus and asthma, closed a $22M Series B financing. Participants include Essex Woodlands.
Thanx for your patience as we catch-up.

Edison Pharmaceuticals (Mountain View, CA) a clinical-stage small molecule company focused on mitochondrial disease Friedreich’s ataxia, closed a $4.1M Series E financing. Participants were not identified.
Thanx for your patience as we catch-up.

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures.
Thanx for your patience as we catch-up.

Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund.
Thanx for your patience as we catch-up.

SeeChange Health (San Francisco, CA) a commercial-stage health management company focused on data analytics and interactive personal health records, closed a $20M Series B financing. Participants include Maverick Capital and Psilos Group.
Thanx for your patience as we catch-up.

Circle Cardiovascular Imaging (Canada) a commercial-stage analytical software company focused on cardiac imaging, closed a $3.9M Series B financing. Participants include Business Development Bank of Canada, Foundation Equity and First Yellowhead Equities.
Thanx for your patience as we catch-up.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.
Thanx for your patience as we catch-up.

Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.
Thanx for your patience as we catch-up.

nanoMR (Albuquerque, NM) a development stage medical device focused on a immunomagnetic capture system for the blood culture market, closed a $13M Series B financing. Participants include Excel Venture Management, Healthcare Ventures, vSpring Capital, Dow Chemical Company and Sun Mountain Capital.
Thanx for your patience as we catch-up.

Intuity Medical (Sunnyvale, CA) a clinical-stage diagnostic device company focused on all-in-one blood sample collection and glucose analysis, closed a $12M Series D financing, bringing the total round to $76M. Participants include Accuitive Medical Ventures, Investor Growth Capital, Thomas McNerney, Venrock, Versant Ventures and U.S. Venture Partners.
Thanx for your patience as we catch-up.

Cleveland Heartlab (Cleveland, OH) a commercial-stage specialty clinical laboratory and disease management company focused on assessing cardiovascular risk, closed a $18.4M Series B financing. Participants include Excel Venture Management and HealthCare Ventures.
Thanx for your patience as we catch-up.